David Propper

David Propper

UNVERIFIED PROFILE

Are you David Propper?   Register this Author

Register author
David Propper

David Propper

Publications by authors named "David Propper"

Are you David Propper?   Register this Author

22Publications

657Reads

40Profile Views

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.

Cancer Chemother Pharmacol 2013 Dec 2;72(6):1213-22. Epub 2013 Oct 2.

Drug Development Unit, The Royal Marsden Hospital, Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2286-7DOI Listing
December 2013

HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.

Exp Mol Pathol 2013 Feb 12;94(1):103-8. Epub 2012 Sep 12.

Centre for Digestive Diseases, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, Whitechapel, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2012.09.001DOI Listing
February 2013

Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion.

Mol Cancer 2013 Jan 3;12. Epub 2013 Jan 3.

Centre for Digestive Diseases, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, Whitechapel, London, E1 2AT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-12-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544714PMC
January 2013

A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers.

Int J Cancer 2012 Mar 3;130(5):1082-92. Epub 2011 Aug 3.

Centre for Digestive Diseases, Blizard Institute for Cell and Molecular Sciences, Barts and The London, Whitechapel, London, United Kingdom.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.26104
Publisher Site
http://dx.doi.org/10.1002/ijc.26104DOI Listing
March 2012

Functional PET imaging in cancer drug development.

Future Oncol 2007 Apr;3(2):215-28

Department of Nuclear Medicine, Queen Mary, University of London, Barts & The London School of Medicine, London, EC1A 7BE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14796694.3.2.215DOI Listing
April 2007

s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line.

Hematol J 2004 ;5(3):247-54

1New Drug Study Group, Barry Reed Oncology Laboratory, St Bartholomew's Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.thj.6200351DOI Listing
September 2004

The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.

Eur J Biochem 2004 Jul;271(13):2773-81

New Drug Study Group, Barry Reed Oncology Laboratory, St. Bartholomew's Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1432-1033.2004.04208.xDOI Listing
July 2004

Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity.

Oncogene 2004 Jan;23(4):981-90

New Drug Study Group, Barry Reed Oncology Laboratory, St Bartholomew's Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1207294DOI Listing
January 2004

Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.

Clin Cancer Res 2003 Jan;9(1):84-92

Imperial Cancer Research Fund Medical Oncology Unit, University of Oxford, Churchill Hospital, Oxford X3 7LJ.

View Article

Download full-text PDF

Source
January 2003